Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BCAS2 CRISPR/Cas9 KO Plasmid (h): sc-405943
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BCAS2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the BCAS2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BCAS2 Antibody (F-5): sc-376554
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BCAS2 CRISPR/Cas9 KO Plasmid (h) | sc-405943 | 20 µg | $397.00 |
Overview
BCAS2 (breast carcinoma amplified sequence 2) encodes a conserved nuclear protein that functions as a core component of the Prp19-associated spliceosome complex and supports pre-mRNA splicing and splice-site fidelity. Through its roles in RNA processing and genome maintenance, BCAS2 influences cell-cycle progression, transcriptional programs, and cellular stress responses. Altered BCAS2 expression and splicing dysregulation have been associated with oncogenic phenotypes in multiple tumor contexts, linking this factor to pathways that govern proliferation and DNA damage signaling. As a regulator of RNA maturation, BCAS2 is also relevant for studying spliceosome-dependent vulnerabilities and broad transcriptomic remodeling in human cells.
BCAS2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BCAS2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BCAS2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BCAS2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BCAS2 protein expression.
This CRISPR knockout system enables efficient generation of BCAS2-deficient cell models for investigation of BCAS2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting BCAS2 exon(s) critical for BCAS2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple BCAS2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by BCAS2 CRISPR/Cas9 KO Plasmid (h) and BCAS2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the BCAS2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by BCAS2 HDR Plasmid (h) and BCAS2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by BCAS2 homology arms to support homology-directed repair at defined BCAS2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.